Hey guys I stumbled across this little OTC stem cell company play that had some significant new released early Friday Morning...It could get more attention this coming week with the SC sector remaining a haven for your hard earned money...
International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will not be immune rejected after transplantation into millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true "Stem Cell Bank" and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: ISCO – Welcome to International Stem Cell Corporation<.
Here are the juicy details of what they've recently accomplished...Link to story is below...
ISCo has found a way of producing embryonic-like stem cells from unfertilised eggs. The egg is chemically stimulated to create a group of cells that form a non-viable (and unfertilised) “embryo”. This, explains Kenneth Aldrich, the firm’s boss, is something that could not be implanted into a woman’s womb and produce a child. Nonetheless, the cells it contains have the same characteristics as stem cells.
Besides any ethical advantages this procedure may have, it could also have medical ones. Because lines of stem cells created in this way have only one parent, they are immunologically simpler than normal embryonic cells—in other words they have a smaller variety of the proteins that trigger rejection. That lack of variety, says Dr Aldrich, means it might be feasible to create a bank of stem-cell lines that could be matched to every immune type in the human population, rather as a blood bank carries blood of all the different groups (A, B, O and so on). Replacement stem cells might then be ordered off the shelf.
Nor are spinal-cord injuries the only condition lined up for treatment. Both ISCo and Advanced Cell Technology, of Los Angeles, are trying to create stem cells that could stop—and possibly reverse—a process called macular degeneration, which leads to blindness. ISCo says it hopes to start human trials later this year. Using embryonic stem cells in this way is regarded as a particularly promising route because a similar form of treatment that employs stem cells recovered from still-born children is already known to work.
StemCellPatents.com Applauds ISCO - StemCellPatents.com
Chart looks good and the volume is building...
ISCO - International Stem Cell Corporation 
Linear Mode
